Pharma Sector

The policy covers pharmaceutical products, bulk drugs, active pharmaceutical ingredients, key starting materials, drug intermediates, medical devices and related manufacturing infrastructure

The company is evaluating specialised CROs, data-management and patient-recruitment businesses as it looks to expand across the pharmaceutical value chain

The US-based company said it is eyeing continued double-digit growth in India driven by rising demand from biopharma, semiconductor, and clean energy sectors

Homegrown pharma major Lupin Ltd has reported a 16 per cent rise in consolidated profit after tax at Rs 1,416.98 crore in the first quarter ended June 30, riding on robust growth across its key markets. The company had posted a consolidated Profit After Tax (PAT) at Rs 1,221.46 crore in the corresponding period last fiscal, Lupin Ltd said in a regulatory filing on Thursday. Consolidated total revenue from operations in the first quarter was at Rs 8,276.89 crore as against Rs 6,268.34 crore in the year-ago period, it added. Total expenses in the quarter under review rose at Rs 6,389.83 crore as compared to Rs 4,931.84 crore in the corresponding period last fiscal, the company said. Commenting on the performance, Lupin Ltd Managing Director Nilesh Gupta said, "We are pleased to begin FY27 with a strong performance, driven by robust growth across our key markets and continued improvement in profitability." The company's focus on execution, operational excellence, and sustained ...

India's pharma industry must pivot from global leadership in generics to innovation, backed by stronger policy, R&D funding and regulatory reforms, says Satish Reddy

A potential deal would carry regulatory risk because of concerns about how it might be assessed by US antitrust authorities under ‌President Donald Trump's administration

Industry seeks AI-based submission tools and unified digital portals to accelerate approvals and compliance tracking

Brokerages see an 11 per cent topline growth in Q1 FY27. HDFC Securities said that the US generic business will be muted due to the absence of gRevlimid, while the India business may grow 13 per cent.

: Biocon Ltd on Wednesday said it has received notice of compliance approval from Canadian health regulator for its Yesintek (ustekinumab) autoinjector, indicated for the treatment of moderate to severe plaque psoriasis. The company's subsidiary in Canada has received Notice of Compliance (NOC) approval for Yesintek (ustekinumab) Autoinjector 45 mg/0.05 mL and 90 mg/mL from Health Canada, Biocon Ltd said in a regulatory filing. Health Canada previously granted NOC for Yesintek (solution for subcutaneous injection) 45 mg/0.5ml (prefilled syringe and vial) and 90 mg/ml (prefilled syringe) and Yesintek I.V. (solution for intravenous infusion) 130 mg/26 mL (5mg/mL) in October 2025, it added. The availability of the Yesintek autoinjector provides patients with an option that the originator product does not offer in Canada, the company said . The new format will allow customised treatment approaches across care settings and patient needs, it added. Biocon said Yesintek is indicated for

From generics to global leadership, India's pharmaceutical industry has transformed since 1991. Its next challenge is becoming a global hub for breakthrough drug innovation

Dahej facility to begin commercial production in FY28; company targets nutraceuticals, functional foods and import substitution

Share price of Rubicon Research hit a new high of ₹1,545.60, rallying 6 per cent on the BSE in Thursday's intra-day deals in an otherwise weak market.

Imported generics to remain tariff-free for two years; industry doubts US can build a cost-competitive manufacturing ecosystem within the transition period

The proposed steep tariffs announced by the US on generic medicines could significantly affect India's largest pharmaceutical export market, economic think tank GTRI said on Wednesday. However, it said that the impact is unlikely to be uniform. "Many Indian generic medicines sell for seven to ten times less than branded alternatives. Even after a 100 per cent tariff, many products could remain cheaper than branded medicines, meaning much of the additional cost would likely be passed on to US healthcare providers, insurers and patients rather than immediately eliminating Indian exports," it said. It added that the greatest pressure is expected to fall on higher-value generic formulations and branded generics, where manufacturing in the United States could become commercially viable. "The proposed tariffs could significantly affect India's largest pharmaceutical export market," Global Trade Research Initiative (GTRI) founder Ajay Srivastava said, adding that India should also reduce

Hospitals and diagnostics are expected to outperform in Q1FY27, driven by capacity additions, improving utilisation and higher patient volumes despite pressure on margins

New company to raise capital for global clinical trials; Lupin to retain significant equity stake and provide seed funding

Divi's Laboratories MD Murali K Divi topped India's pharma executive pay chart in FY26 with ₹100.26 crore, driven almost entirely by profit-linked commission

According to reports, Mylan, which is part of Viatris, planned to sell up to 5.64 per cent stake in Biocon, worth up to ₹3,481 crore in block deals today.

Restructuring positions biotech arm to focus on biologics and biosimilar

Drugmaker says it will supply 6-7 million pens in the last two quarters of FY27 and restart production by November after resolving the API-related quality issue